Why More Does Not Automatically Mean More Performance

The entire series can be reduced to one lesson: the body is not a machijne in which every setting can be pushed to maximum without consequences. Every system has limits, feedback and costs. A substance may increase an effect up to a point, after which benefit plateaus while risk continues to rise.

1. Dose-Response Relationships

In pharmacology, dose and effect do not always increase linearly. Some substances have curves in which early exposure produces large effects while later increases provide little additional benefit. Adverse effects may continue to increase. This is one reason therapeutic windows matter.

2. The Effect Plateau

Receptors, enzymes and physiological systems have limited capacity. Beyond a certain point, more substance does not create proportionally more effect. It may instead increase tissue exposure and the probability of adverse events.

3. Biological Cost

An acute advantage may come with higher blood pressure, poorer sleep, dehydration, liver stress, renal effects, endocrine disruption or psychological consequences. If the benefit is small and the cost is large, the final balance becomes unfavorable.

4. Tolerance

Some substances produce tolerance: the body adapts and the response to the same exposure decreases. This can create pressure to increase exposure and turn a performance strategy into a pharmacological cycle. Tolerance does not mean that risk has disappeared.

5. Interactions

Multiple substances can create additive effects. A stimulant, a medicine affecting hydration and a night of poor sleep may all push physiology in the same direction. Each factor may seem tolerable alone while the combination exceeds physiological reserve.

6. Performance Versus Recovery

Performance in one session is not the only important outcome. An athlete must be able to repeat effort two days later, a week later and throughout a season. An intervention that improves acute output while reducing sleep or recovery can have a negative long-term balance.

7. Individual Responses

People do not respond identically to the same substance. Genetics, age, liver and kidney function, body composition, training, sleep and other medicines can change the response. Another athlete's experience is therefore not a universal pharmacological truth.

8. The Myth That If It Works, It Is Good

A treatment can have a real biological effect and still be inappropriate for a healthy athlete. A measurable outcome does not by itself show that benefit outweighs risk. Clinical pharmacology exists precisely to evaluate that balance.

9. Anti-Doping and Sporting Limits

The WADA List adds an external limit. Even if a substance has a physiological effect, it may be prohibited to protect athletes and competition integrity. Performance pharmacology therefore has to respect both medicine and sporting regulation.

10. The Lesson of the Series

Performance pharmacology is not a collection of tricks. It is the study of interactions between substances and physiology. The better we understand mechanisms, the clearer it becomes why every benefit has a limit and why crossing that limit can turn an advantage into a medical problem.

11. Conclusion

In performance, «more» is tempting because results are measurable: kilograms, seconds, centimeters and repetitions. The body measures something else: pressure, temperature, glucose, electrolytes, sleep, inflammation and cardiovascular stress. When a system is pushed beyond its physiological window, the result is not necessarily performance. It may simply be cost.

Key Scientific Sources

Warrier AA et al. Performance-Enhancing Drugs in Healthy Athletes: An Umbrella Review of Systematic Reviews and Meta-analyses, 2024. World Anti-Doping Agency. 2026 Prohibited List. Clinical pharmacology literature on dose-response relationships, therapeutic windows and drug interactions.

Editorial note: this series is educational and does not provide use protocols, doses or combinations for performance enhancement.